Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Heterotaxy, Asplenia : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
References

Related Articles
Acidosis, Metabolic

Dextrocardia

Heterotaxy, Polysplenia

Transposition of the Great Arteries




Patient Education
Click here for patient education.



Author: Kevin M Shannon, MD, Associate Professor, Division of Pediatric Cardiology, Director of Pediatric Electrophysiology Program, UCLA School of Medicine; Consulting Staff, Pediatric Cardiology Clinic, Olive View-UCLA Medical Center

Kevin Shannon is a member of the following medical societies: American Academy of Pediatrics

Editors: Charles Berul, MD, Associate Professor of Pediatrics, Harvard Medical School; Senior Associate, Department of Cardiology, Children's Hospital of Boston; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc; Julian M Stewart, MD, PhD, Director of Center for Pediatric Hypotension, Professor, Departments of Pediatrics and Physiology, Division of Pediatric Cardiology, Westchester Medical Center and New York Medical College; Gilbert Herzberg, MD, Assistant Professor, Department of Pediatrics, Section of Pediatric Cardiology, New York Medical College; Stuart Berger, MD, Professor of Pediatrics, Division of Cardiology, Medical College of Wisconsin; Chief of Pediatric Cardiology, Medical Director of Pediatric Heart Transplant Program, Medical Director of The Heart Center, Children's Hospital of Wisconsin

Author and Editor Disclosure

Synonyms and related keywords: right atrial isomerism, laterality defects, cyanotic congenital heart disease, intestinal malrotation, asplenia

Background

Asplenia is a heterogeneous disease that primarily affects the asymmetric organs, including the heart, liver, intestines, and spleen. The first published description of asplenia appeared in 1826. Primary manifestations of this disease include cyanotic congenital heart disease, asplenia, and intestinal malrotation.

Pathophysiology

The exact cause of asplenia has not been defined, but it appears to be multifactorial, with some familial predisposition. Embryologically, it results from failure of development of right-left asymmetry. All thoracic and abdominal organs can be affected; however, other than the anatomic abnormalities, the function of these organs is affected minimally.

Cardiac manifestations can range from minor to severe and are related to incomplete or impaired rotation of the heart. Common cardiac findings include persistence of a left-sided superior vena cava (SVC), anomalous pulmonary venous return, common atrium, endocardial cushion defects, and double outlet right ventricle. In addition, bilateral right atrial appendages may be present in at least 20% of patients with asplenia, and their presence is diagnostic of this syndrome. Other thoracic findings include bilateral morphologic right bronchi and trilobed lungs.

Abdominal findings can include asplenia, transverse liver, and intestinal malrotation. Biliary tract abnormalities have also been described but are rarely of clinical significance.

Frequency

United States

Asplenia has a prevalence of less than 0.1%, but it may account for as much as 1% of the newborn mortality rate. Case reports of familial predisposition exist, but no clear inheritance pattern or gene has been identified. Anatomic findings have been variable in the families described.

Mortality/Morbidity

Without surgery, the mortality rate of asplenia is 95% in the first year of life. Palliative cardiac surgery improves the survival rate, particularly during infancy, but the 5-year mortality rate remains as high as 50%. Mortality can result from congenital heart disease, intestinal malrotation, or sepsis. In one large retrospective review from Canada, the 1-year mortality rate was 80%.

Race

No predilection based on race has been reported.

Sex

No predilection based on sex has been reported.

Age

Heterotaxy occurs in utero, and the onset of clinical symptoms may be during the neonatal period or later in life, depending on the exact cardiac and visceral lesions.



History

Patients usually present with symptoms of congenital heart disease in the newborn period. The most common presenting symptom is cyanosis, but murmurs and signs of congestive heart failure can also be presenting signs. A small percentage of patients present with abdominal symptoms or are identified because of an incidental finding of situs abnormalities (eg, dextrocardia, intestinal malrotation). Typically, patients presenting after the newborn period do not have significant congenital heart disease.

Physical

Cyanosis and/or congestive heart failure are the most common physical findings in patients who present in the newborn period. A transverse liver or dextrocardia is often present. Patients who present after the newborn period have predominantly normal physical examination findings, other than a transverse liver and/or dextrocardia. Patients who present with symptoms of malrotation can present with an acute abdomen caused by volvulus.

Causes

The causes of asplenia are unknown, but they appear to be multifactorial and may include inherited predisposition, teratogenic factors, or infection. No racial, sexual, or socioeconomic predispositions exist. Although familial cases have been reported, no genes or loci have been identified. Reported patterns of inheritance have been diverse. In several families with multiple affected children, parental consanguinity is present, or rarely an autosomal recessive inheritance pattern is observed. In at least one family, an X-linked inheritance pattern was reported, with the disease present in 11 related males over 2 generations. Different forms of heterotaxy, including asplenia and polysplenia, may occur within the same family.

The molecular basis for heterotaxy may relate to defects in genes responsible for laterality, such as the growth factor genes: nodal, activin, and lefty.



Acidosis, Metabolic
Dextrocardia
Heterotaxy, Polysplenia
Transposition of the Great Arteries

Other Problems to be Considered

Kartagener syndrome



Lab Studies

  • Useful laboratory studies include a CBC with peripheral smear to assess for Howell-Jolly bodies and evidence of impaired splenic function.
  • Arterial blood gases to assess for cyanotic heart disease may also be indicated.

Imaging Studies

  • Complete echocardiography is indicated in any patient with suspected asplenia to rule out associated congenital heart disease.
  • Routine chest radiography is indicated to determine the cardiac size and location, to assess the bronchial anatomy, and to assess abdominal situs.
  • In addition, an upper GI study has been proposed as a routine study in asplenic patients because of the high incidence of intestinal malrotation and the risk of volvulus.

Other Tests

  • Liver-spleen scanning is indicated to confirm the presence of functional splenic tissue.
  • A 12-lead ECG is helpful in assessing patients with asplenia because an abnormal P wave axis is common, and conduction system abnormalities, including complete heart block, sick sinus syndrome, and supraventricular tachycardia (SVT), may occur, although they are less common than in polysplenia.
  • Additional studies of cardiac conduction may be indicated based on the clinical setting and ECG findings; in particular, 24-hour Holter monitoring may be recommended.

Procedures

  • Cardiac catheterization
    • Patients presenting with cardiac malformations often require cardiac catheterization on one or more occasions. In the newborn period, cardiac catheterization may be indicated to assess systemic and pulmonary venous connections, if this information cannot be obtained from echocardiography. Access can often be achieved through the femoral vein or the umbilical vein, although umbilical venous cannulation is more difficult in patients with asplenia than in those with most other congenital malformations. Venous access from the umbilicus or femoral vein is usually sufficient to perform both a right- and left-heart catheterization.
    • Later, cardiac catheterization may be indicated to determine individual candidacy for surgical intervention. Indications for catheterization may include assessment of pulmonary vascular resistance before palliation with a cavopulmonary connection. Assess pulmonary venous drainage in patients with unobstructed anomalous pulmonary venous return. In such cases, ruling out mild obstruction to pulmonary venous return, as is often observed on anomalous return to a confluence behind the right atrium or to the proximal SVC, is important. Other indications for cardiac catheterization include assessment of ventricular size and visualization and potential embolization of aortopulmonary collateral vessels. Finally, electrophysiological testing may be indicated based on the clinical rhythm presentation.



Medical Care

Medical therapy is typically directed at the findings of the initial evaluation. Anticongestive medication often is beneficial preoperatively in patients with significant left-to-right shunts. Patients with functional asplenia require long-term antibiotic prophylaxis and the pneumococcal vaccine.

Surgical Care

Surgical care is also directed at the findings of the initial evaluation. Patients with significant cardiac disease may require staged palliation or definitive repair. Patients with biliary atresia may require initial palliative surgery followed by liver transplantation.

Consultations

Patients with heterotaxy should have a comprehensive evaluation by a pediatric cardiologist. Depending on the clinical circumstances, an assessment by a pediatric gastroenterologist, pediatric cardiac surgeon, pediatric cardiac electrophysiologist, and/or pediatric anesthesiologist may be warranted.



Patients with congestive cardiomyopathy with significant left-to-right shunts may benefit from treatment for congestive heart failure. In patients with functional asplenia, pneumococcal vaccine and antibiotics for subacute bacterial endocarditis (SBE) prophylaxis are necessary. Antibiotic prophylaxis is administered to patients before procedures that may cause bacteremia are performed. For more information, see Antibiotic Prophylactic Regimens for Endocarditis.

Drug Category: Diuretic agents

Promote excretion of water and electrolytes by the kidneys. Used to treat heart failure or hepatic, renal, or pulmonary disease when sodium and water retention has resulted in edema or ascites. May be used as monotherapy or in combination to treat hypertension.

Drug NameFurosemide (Lasix)
DescriptionUsed to treat edema. Increases excretion of water by interfering with chloride-binding cotransport system, which, in turn, inhibits sodium and chloride reabsorption in ascending loop of Henle and distal renal tubule. Dose must be individualized to patient. Depending on response, administer at increments of 20-40 mg, no sooner than 6-8 h after previous dose, until desired diuresis occurs. When treating infants, titrate with 1-mg/kg/dose increments until satisfactory effect achieved.
Adult Dose20-80 mg/d PO/IV/IM; may titrate up to 600 mg/d for severe edematous states
Pediatric Dose3-6 mg/kg/d PO divided tid
ContraindicationsDocumented hypersensitivity; hepatic coma; anuria; state of severe electrolyte depletion
InteractionsMetformin decreases furosemide concentrations; furosemide interferes with hypoglycemic effect of antidiabetic agents and antagonizes muscle-relaxing effect of tubocurarine; auditory toxicity appears to be increased with coadministration of aminoglycosides and furosemide; hearing loss of varying degrees may occur; anticoagulant activity of warfarin may be enhanced when taken concurrently with this medication; increased plasma lithium levels and toxicity are possible when taken concurrently with this medication
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsPerform frequent serum electrolyte, carbon dioxide, glucose, creatinine, uric acid, calcium, and BUN determinations during first few months of therapy and periodically thereafter

Drug NameSpironolactone (Aldactone)
DescriptionFor management of edema resulting from excessive aldosterone excretion. Competes with aldosterone for receptor sites in distal renal tubules, increasing water excretion while retaining potassium and hydrogen ions.
Adult Dose25-200 mg/d PO divided q12-24h
Pediatric Dose1-3 mg/kg/d PO divided tid
ContraindicationsDocumented hypersensitivity; anuria; renal failure; hyperkalemia
InteractionsMay decrease effect of anticoagulants; potassium and potassium-sparing diuretics may increase toxicity of spironolactone
PregnancyD - Unsafe in pregnancy
PrecautionsCaution in renal and hepatic impairment

Drug Category: Inotropic agents

Positive inotropes increase the force of contraction of the myocardium and are used to treat acute and chronic congestive heart failure. Some may also increase or decrease the heart rate (eg, positive or negative chronotropic agents), provide vasodilatation, or improve myocardial relaxation. These additional properties influence the choice of drug for specific circumstances. Those used predominantly for their inotropic effects include cardiac glycosides and phosphodiesterase inhibitors.

Drug NameDigoxin (Lanoxin)
DescriptionUsed to treat congestive heart failure. Cardiac glycoside with direct inotropic effects in addition to indirect effects on the cardiovascular system. Acts directly on cardiac muscle, increasing myocardial systolic contractions. Its indirect actions result in increased carotid sinus nerve activity and enhanced sympathetic withdrawal for any given increase in mean arterial pressure.
Adult Dose0.125-0.375 mg PO qd
Pediatric Dose10 mcg/kg/d PO divided bid
ContraindicationsDocumented hypersensitivity; beriberi heart disease; idiopathic hypertrophic subaortic stenosis; constrictive pericarditis; carotid sinus syndrome
InteractionsIV calcium may produce arrhythmias in digitalized patients
Medications that may increase digoxin levels include alprazolam, benzodiazepines, bepridil, captopril, cyclosporine, propafenone, propantheline, quinidine, diltiazem, aminoglycosides, PO amiodarone, anticholinergics, diphenoxylate, erythromycin, felodipine, flecainide, hydroxychloroquine, itraconazole, nifedipine, omeprazole, quinine, ibuprofen, indomethacin, esmolol, tetracycline, tolbutamide, and verapamil Medications that may decrease serum digoxin levels include aminoglutethimide, antihistamines, cholestyramine, neomycin, penicillamine, aminoglycosides, PO colestipol, hydantoins, hypoglycemic agents, antineoplastic treatment combinations (including carmustine, bleomycin, methotrexate, cytarabine, doxorubicin, cyclophosphamide, vincristine, and procarbazine), aluminum or magnesium antacids, rifampin, sucralfate, sulfasalazine, barbiturates, kaolin/pectin, and aminosalicylic acid
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsHypokalemia may reduce positive inotropic effect of digitalis; hypercalcemia predisposes patient to digitalis toxicity, and hypocalcemia can make digoxin ineffective until serum calcium levels are within the reference range; magnesium replacement therapy must be instituted in patients with hypomagnesemia to prevent digitalis toxicity; patients diagnosed with incomplete AV block may progress to complete block when treated with digoxin; exercise caution in hypothyroidism, hypoxia, and acute myocarditis; adjust dose in renal impairment; highly toxic (overdoses can be fatal)

Drug Category: Angiotensin-converting enzyme (ACE) inhibitors

ACE inhibitors are beneficial in all stages of congestive heart failure. Pharmacologic effects result in a decrease in systemic vascular resistance, reducing blood pressure, preload, and afterload. Dyspnea and exercise tolerance are improved. Unlike diuretics, studies demonstrate improvement of survival and reduced progression of mild or moderate heart failure to more severe stages. Benefits asymptomatic left ventricular dysfunction.

Drug NameEnalapril (Vasotec)
DescriptionUsed to treat congestive heart failure. Competitive inhibitor of ACE. Reduces angiotensin II levels, decreasing aldosterone secretion.
Adult Dose2.5-5 mg/d PO (increase prn)
10-40 mg/d PO in 1-2 divided doses is dosing range
1.25 mg/dose IV infused over 5 min q6h
Pediatric Dose0.1 mg/kg/d PO initially; may gradually titrate upward; not to exceed 0.5 mg/kg/d PO divided bid
ContraindicationsDocumented hypersensitivity
InteractionsNSAIDs may reduce hypotensive effects of enalapril; ACE inhibitors may increase digoxin, lithium, and allopurinol levels; rifampin decreases enalapril levels; probenecid may increase enalapril levels; the hypotensive effects of ACE inhibitors may be enhanced when administered concurrently with diuretics
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsCategory D in second and third trimester of pregnancy; caution in renal impairment, valvular stenosis, or severe CHF

Drug Category: Vaccines

Active immunization increases resistance to infection. Vaccines consist of microorganisms or cellular components, which act as antigens. Administration of the vaccine stimulates the production of antibodies with specific protective properties.

Drug NamePneumococcal vaccine (Pneumovax-23, Pnu-Imune 23)
DescriptionPolyvalent vaccine used for prophylaxis against infection from Streptococcus pneumoniae. Used in populations at increased risk of pneumococcal pneumonia (ie, age >55 y, chronic infection, asplenia, immunocompromise).
Adult Dose0.5 mL IM/SC once
Pediatric Dose<2 years: Contraindicated (antibody response is poor in this age group)
>2 years: 0.5 mL IM/SC; repeat dose after 3-5 y for high-risk children (eg, functional or anatomic asplenia, conditions associated with rapid antibody decline after initial vaccination)
ContraindicationsDocumented hypersensitivity to any component or to thimerosal; severe or even a moderate febrile illness; age <2 y; thrombocytopenia or any coagulation disorder that would contraindicate IM injection unless potential benefit clearly outweighs risk of administration
InteractionsImmunosuppressive agents (eg, large amounts of corticosteroids, antimetabolites, alkylating agents, cytotoxic agents) may reduce effectiveness; therapy with immunoglobulin preparations is likely to block the active immunity induced with pneumococcal vaccination, withhold for 3 mo after discontinuation of immunoglobulin therapy
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsMay cause relapse in patients with stable idiopathic thrombocytopenia purpura; adverse effects include arthralgia, fever, urticaria, and Guillain-Barré syndrome (rarely)

Drug Category: Antibiotics, prophylactic

Antibiotic prophylaxis is administered to patients before performing procedures that may cause bacteremia.

Drug NameAmoxicillin (Amoxil, Trimox)
DescriptionInterferes with synthesis of cell wall mucopeptides during active multiplication, resulting in bactericidal activity against susceptible bacteria. Used as prophylaxis in minor procedures.
Adult Dose2 g PO 1 h before procedure
Alternatively, 3 g PO 1 h before procedure, followed by 1.5 g PO 6 h after initial dose
Pediatric Dose50 mg/kg PO 1 h before procedure; not to exceed 2 g/dose
ContraindicationsDocumented hypersensitivity
InteractionsReduces efficacy of PO contraceptives
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in renal impairment

Drug NameAmpicillin (Marcillin, Omnipen)
DescriptionFor prophylaxis in patients undergoing dental, oral, or respiratory tract procedures.
Coadministered with gentamicin for prophylaxis in GI or genitourinary procedures.
Adult Dose2 g IV/IM 30 min before procedure
High-risk patients: 2 g ampicillin IV/IM plus gentamicin 1.5 mg/kg IV 30 min before procedure, followed 6 h later by 1 g ampicillin IV/IM or 1 g amoxicillin PO
Pediatric Dose50 mg/kg IV/IM 30 min before procedure; not to exceed 2 g/dose
High-risk patients: 50 mg/kg IV/IM ampicillin plus gentamicin 1.5 mg/kg IV 30 min before procedure, followed 6 h later by ampicillin 25 mg/kg IV/IM or amoxicillin 25 mg/kg PO
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid and disulfiram elevate levels; allopurinol decreases effects and has additive effects on ampicillin rash; may decrease effects of PO contraceptives
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in renal failure; evaluate rash and differentiate from hypersensitivity reaction

Drug NameClindamycin (Cleocin)
DescriptionUsed in penicillin-allergic patients undergoing dental, oral, or respiratory tract procedures. Useful for treatment against streptococcal and most staphylococcal infections.
Adult Dose600 mg PO/IV 1 h before procedure and 150 mg PO/IV 6 h after first dose
Pediatric Dose20 mg/kg PO 1 h or 20 mg/kg IV 30 min before procedure; not to exceed 600 mg/dose
ContraindicationsDocumented hypersensitivity; regional enteritis; ulcerative colitis; hepatic impairment; antibiotic-associated colitis
InteractionsIncreases duration of neuromuscular blockade induced by tubocurarine and pancuronium; erythromycin may antagonize effects; antidiarrheals may delay absorption
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis

Drug NameGentamicin (Garamycin)
DescriptionAminoglycoside antibiotic for gram-negative coverage. Used in combination with an agent against gram-positive organisms and one that covers anaerobes.
Used in conjunction with ampicillin or vancomycin for prophylaxis in GI or genitourinary procedures.
Adult Dose1.5 mg/kg IV; not to exceed 120 mg/dose; administer with ampicillin 2 g IV 30 min before procedure
Pediatric Dose1.5 mg/kg IV 30 min before procedure; not to exceed 120 mg/dose; administer with ampicillin 50 mg/kg IV; not to exceed 2 g/dose
ContraindicationsDocumented hypersensitivity; non–dialysis-dependent renal insufficiency
InteractionsCoadministration with other aminoglycosides, cephalosporins, penicillins, and amphotericin B may increase nephrotoxicity; because aminoglycosides enhance effects of neuromuscular blocking agents, prolonged respiratory depression may occur; coadministration with loop diuretics may increase auditory toxicity of aminoglycosides; possible irreversible hearing loss of varying degrees may occur (monitor regularly)
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsNarrow therapeutic index (not intended for long-term therapy); caution in renal failure (patient not on dialysis), myasthenia gravis, hypocalcemia, and conditions that depress neuromuscular transmission; adjust dose in renal impairment

Drug NameVancomycin (Vancocin)
DescriptionPotent antibiotic directed against gram-positive organisms and active against Enterococcus species. Useful in the treatment of septicemia and skin structure infections. Indicated for patients who cannot receive or have not responded to penicillins and cephalosporins or have infections with resistant staphylococci.
Use CrCl to adjust dose in renal impairment.
Used in conjunction with gentamicin for prophylaxis in penicillin-allergic patients undergoing GI or genitourinary procedures.
Adult DoseDental, PO, or upper respiratory tract surgery: 1 g IV infused over 1 h, 1 h before procedure
GI/GU procedures: 1 g IV plus gentamicin 1.5 mg/kg IV infused over 1 h, 1 h before surgery
Pediatric DoseDental, PO, or upper respiratory tract surgery: 20 mg/kg IV infused over 1 h, 1 h before procedure
ContraindicationsDocumented hypersensitivity
InteractionsErythema, histaminelike flushing, and anaphylactic reactions may occur when administered with anesthetic agents; when taken concurrently with aminoglycosides, the risk of nephrotoxicity may increase above that with aminoglycoside monotherapy; effects in neuromuscular blockade may be enhanced when coadministered with nondepolarizing muscle relaxants
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsCaution in renal failure and neutropenia; red man syndrome is caused by too rapid IV infusion (dose administered over a few min) but rarely happens when dose is administered IV over 2 h or as PO/IP administration; red man syndrome is not an allergic reaction

Drug NameCefazolin (Ancef)
DescriptionFirst-generation semisynthetic cephalosporin that arrests bacterial cell wall synthesis, inhibiting bacterial growth. Primarily active against skin flora, including Staphylococcus aureus.
Adult Dose1 g IV/IM within 30 min before procedure
Pediatric Dose25 mg/kg IV/IM within 30 min before procedure; not to exceed 1 g/dose
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid prolongs effect; coadministration with aminoglycosides may increase renal toxicity; may yield false-positive urine-dip test results for glucose
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in renal impairment; superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy

Drug NameCephalexin (Keflex)
DescriptionFirst-generation cephalosporin that arrests bacterial growth by inhibiting bacterial cell wall synthesis. Bactericidal activity against rapidly growing organisms. Primary activity against skin flora and used for skin infections or prophylaxis in minor procedures.
Adult Dose2 g PO 1 h before procedure
Pediatric Dose50 mg/kg PO 1 h before procedure; not to exceed 2 g/dose
ContraindicationsDocumented hypersensitivity
InteractionsCoadministration with aminoglycosides increases nephrotoxic potential
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in renal impairment

Drug NameCefadroxil (Duricef)
DescriptionFirst-generation cephalosporin that arrests bacterial growth by inhibiting bacterial cell wall synthesis. Bactericidal activity against rapidly growing organisms. Primary activity against skin flora and used for skin infections or prophylaxis in minor procedures.
Adult Dose2 g PO 1 h before procedure
Pediatric Dose50 mg/kg PO 1 h before procedure; not to exceed 2 g/dose
ContraindicationsDocumented hypersensitivity
InteractionsCoadministration with furosemide or aminoglycosides may increase nephrotoxicity; probenecid prolongs effects
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in renal impairment; superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy

Drug NameAzithromycin (Zithromax)
DescriptionInhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest.
Adult Dose500 mg PO 1 h before procedure
Pediatric Dose15 mg/kg PO 1 h before procedure; not to exceed 500 mg/dose
ContraindicationsDocumented hypersensitivity; hepatic impairment; administration with pimozide
InteractionsMay increase toxicity of theophylline, warfarin, and digoxin; effects are reduced with coadministration of aluminum and/or magnesium antacids; nephrotoxicity and neurotoxicity may occur when coadministered with cyclosporine
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsBacterial or fungal overgrowth may result from prolonged antibiotic use; may increase hepatic enzymes and cholestatic jaundice; caution in patients with impaired hepatic function, prolonged QT intervals, or pneumonia; caution in patients who are hospitalized, geriatric, or debilitated

Drug NameClarithromycin (Biaxin)
DescriptionInhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest.
Adult Dose500 mg PO 1 h before procedure
Pediatric Dose15 mg/kg PO 1 h before procedure; not to exceed 500 mg/dose
ContraindicationsDocumented hypersensitivity; coadministration of pimozide
InteractionsToxicity increases with coadministration of fluconazole, astemizole, and pimozide; effects decrease and GI adverse effects may increase with coadministration of rifabutin or rifampin; may increase toxicity of anticoagulants, cyclosporine, tacrolimus, digoxin, omeprazole, carbamazepine, ergot alkaloids, triazolam, and HMG CoA-reductase inhibitors; cardiac arrhythmias may occur with coadministration of cisapride; plasma levels of certain benzodiazepines may increase, prolonging CNS depression; arrhythmias and increases in QTc intervals occur with disopyramide; coadministration with omeprazole may increase plasma levels of both agents
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsCoadministration with ranitidine or bismuth citrate not recommended with CrCl <25 mL/min; administer half dose or increase dosing interval if CrCl <30 mL/min; diarrhea may be sign of pseudomembranous colitis; superinfections may occur with prolonged or repeated antibiotic therapies



Prognosis

  • Without surgery, the mortality rate of asplenia is 95% in the first year of life. Palliative cardiac surgery improves the survival rate, particularly during infancy, but the 5-year mortality rate remains as high as 50%.
  • Antibiotic prophylaxis may be needed in patients with splenic insufficiency.



Medical/Legal Pitfalls

  • Failure to consider gastrointestinal malrotation in patients with cardiac and/or visceral heterotaxy: This may potentially result in delayed diagnosis of gut volvulus.
  • Failure to consider splenic insufficiency in patients with heterotaxy: Liver-spleen scanning and red blood cell examination should be performed to identify spleen function.



  • Atkinson DE, Drant S. Diagnosis of heterotaxy syndrome by fetal echocardiography. Am J Cardiol. Nov 1 1998;82(9):1147-9, A10. [Medline].
  • Bartram U, Wirbelauer J, Speer CP. Heterotaxy syndrome -- asplenia and polysplenia as indicators of visceral malposition and complex congenital heart disease. Biol Neonate. 2005;88(4):278-90. [Medline].
  • Chen SJ, Li YW, Wang JK, et al. Usefulness of electron beam computed tomography in children with heterotaxy syndrome. Am J Cardiol. Jan 15 1998;81(2):188-94. [Medline].
  • Ditchfield MR, Hutson JM. Intestinal rotational abnormalities in polysplenia and asplenia syndromes. Pediatr Radiol. May 1998;28(5):303-6. [Medline].
  • Eronen M, Kajantie E, Boldt T. Right atrial isomerism in four siblings. Pediatr Cardiol. 2004;24:141-4. [Medline][Full Text].
  • Freedom RM, Jaeggi ET, Lim JS, Anderson RH. Hearts with isomerism of the right atrial appendages - one of the worst forms of disease in 2005. Cardiol Young. 2005;15:554-67. [Medline][Full Text].
  • Hashmi A, Abu-Sulaiman R, McCrindle BW, et al. Management and outcomes of right atrial isomerism: a 26-year experience. J Am Coll Cardiol. Apr 1998;31(5):1120-6. [Medline].
  • Hofstaetter C, Plath H, Hansmann M. Prenatal diagnosis of abnormalities of the fetal venous system. Ultrasound Obstet Gynecol. Mar 2000;15(3):231-41. [Medline].
  • Kawahira Y, Kishimoto H, Kawata H, et al. Morphologic analysis of common atrioventricular valves in patients with right atrial isomerism. Pediatr Cardiol. Mar-Apr 1997;18(2):107-11. [Medline].
  • Levine JC, Walsh EP, Saul JP. Radiofrequency ablation of accessory pathways associated with congenital heart disease including heterotaxy syndrome. Am J Cardiol. 1993;72:689-93. [Medline].
  • Mahle WT, Silverman NH, Marx GR, Anderson RH. Echo-morphological correlates concerning the functionally univentricular heart in the setting of isomeric atrial appendages. Cardiol Young. 2006;16 Suppl 1:35-42. [Medline][Full Text].
  • Ruscazio M, Van Praagh S, Marrass AR, et al. Interrupted inferior vena cava in asplenia syndrome and a review of the hereditary patterns of visceral situs abnormalities. Am J Cardiol. Jan 1 1998;81(1):111-6. [Medline].
  • Ticho BS, Van Praagh R. Inherited structural heart diseases associated with arrhythmias: Defects in laterality. In: Berul CI, Towbin JA, eds. Molecular Genetics of Cardiac Electrophysiology. Boston, Mass:. Kluwer Academic Publishers;2000:317-328.
  • Uemura H, Ho SY, Devine WA, Anderson RH. Analysis of visceral heterotaxy according to splenic status, appendage morphology, or both. Am J Cardiol. Oct 15 1995;76(11):846-9. [Medline].
  • Uemura H, Ho SY, Anderson RH, Yagihara T. Ventricular morphology and coronary arterial anatomy in hearts with isometric atrial appendages. Ann Thorac Surg. May 1999;67(5):1403-11. [Medline].
  • Wu MH, Wang JK, Lin JL, et al. Supraventricular tachycardia in patients with right atrial isomerism. J Am Coll Cardiol. Sep 1998;32(3):773-9. [Medline].
  • Yoo SJ, Kim YM, Choe YH. Magnetic resonance imaging of complex congenital heart disease. Int J Card Imaging. Apr 1999;15(2):151-60. [Medline].
  • Zissin R, Rathaus V, Oscadchy A, et al. Intestinal malrotation as an incidental finding on CT in adults. Abdom Imaging. Nov-Dec 1999;24(6):550-5. [Medline].

Heterotaxy, Asplenia excerpt

Article Last Updated: Apr 17, 2006